Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as long when switched to a once-daily oral drug called daraxonrasib, ...
Onco360 ®, the nation’s leading independent Specialty Pharmacy, is grateful to be selected as a pharmacy partner by Revolution Medicines for RASONQUE™ (daraxonrasib), which is an inhibitor of the RAS ...
The benefit of daraxonrasib in PDAC may be overstated in RASolute 302 due to informative censoring. The RASolute 302 trial (NCT06625320) in pancreatic cancer has received a lot of attention. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results